Finally, this meta-analysis did not include venetoclax–rituximab and venetoclax–obinutuzumab regimens, which would have promoted a direct comparison with BTKi monotherapy and will be addressed in further RCTs comparing venetoclax-based therapy to BTKi monotherapy in untreated or previously treated CLL patients. The gene discussed is IBTK; the disease is B-cell chronic lymphocytic leukemia.